treatment

GIST warriors left behind a legacy of struggle & triumph

Access issues come up often enough in America. Depending on the disease, many times there are agencies or organizations in place to help patients in need overcome these hurdles. Outside of the United States, it is not always easy or even difficult to access treatment for a rare cancer. It can be downright impossible. Factors like cost, patient population, and bureaucratic red tape can lead to restrictions on a patient’s ability to afford or even get a prescription for drugs like Gleevec, Sutent and others.

By |2019-09-20T15:21:01-04:00February 1st, 2012|News|

Molecular Clues Help Refine Kinase Inhibitor Strategy for GI

Robert G. Maki, M.D., Ph.D. talks about how molecular clues help refine Kinase Inhibitor strategy for GI. In the post-imatinib (Gleevec) era, treatment of gastrointestinal stromal tumors has shifted from serial surgeries to refinement of kinase [...]

By |2012-10-25T13:15:36-04:00February 1st, 2008|Video|

LRG signs the Bad Nauheim Declaration in Germany

During the weekend of June 30, 2007, representatives of the worldwide GIST community convened in Frankfurt, Germany for the Patient Summit meeting. An important outcome of these deliberations is the "Bad Nauheim Declaration", a statement regarding minimum standards for the treatment of patients with GIST.

By |2014-09-03T12:35:27-04:00July 14th, 2007|News|
Go to Top